Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1128/mSphere.00288-20 http://scihub22266oqcxt.onion/10.1128/mSphere.00288-20 32404512!7227768!32404512     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       mSphere 2020 ; 5 (3): ä Nephropedia Template TP {{tp|p=32404512|t=2020. Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?|pdf=|usr=}}{{32404512}} gab.com Text Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity JO: mSphere http://www.kidney.de/pget.php?&tw=1&pmid=32404512 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS coronavirus 2, or SARS-CoV-2) is the cause of the respiratory infection known as COVID-19. From an immunopathological standpoint, coronaviruses such as SARS-CoV-2 induce increased levels of a variety of T-helper 1 (Th1) and inflammatory cytokines and chemokines, including interleukin-1 (IL-1), IL-6, CCL2 protein, and CXCL10 protein. In the absence of proven antiviral agents or an effective vaccine, substances with immunomodulatory activity may be able to inhibit inflammatory and Th1 cytokines and/or yield an anti-inflammatory and/or Th2 immune response to counteract COVID-19 symptoms and severity. This report briefly describes the following four unconventional but commercially accessible immunomodulatory agents that can be employed in clinical trials to evaluate their effectiveness at alleviating disease symptoms and severity: low-dose oral interferon alpha, microdose DNA, low-dose thimerosal, and phytocannabinoids. Twit Text FOAVip Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity ????mSphere http://www.kidney.de/pget.php?&tw=1&pmid=32404512 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32404512 #FOAvip English Wikipedia <ref>{{Cite pmid|32404512}}</ref> Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity? #MMPMID32404512 Mamber SW; Krakowka S; Osborn J; Saberski L; Rhodes RG; Dahlberg AE; Pond-Tor S; Fitzgerald K; Wright N; Beseme S; McMichael J mSphere 2020[May]; 5 (3): ä PMID32404512show ga Severe acute respiratory syndrome coronavirus 2 (SARS coronavirus 2, or SARS-CoV-2) is the cause of the respiratory infection known as COVID-19. From an immunopathological standpoint, coronaviruses such as SARS-CoV-2 induce increased levels of a variety of T-helper 1 (Th1) and inflammatory cytokines and chemokines, including interleukin-1 (IL-1), IL-6, CCL2 protein, and CXCL10 protein. In the absence of proven antiviral agents or an effective vaccine, substances with immunomodulatory activity may be able to inhibit inflammatory and Th1 cytokines and/or yield an anti-inflammatory and/or Th2 immune response to counteract COVID-19 symptoms and severity. This report briefly describes the following four unconventional but commercially accessible immunomodulatory agents that can be employed in clinical trials to evaluate their effectiveness at alleviating disease symptoms and severity: low-dose oral interferon alpha, microdose DNA, low-dose thimerosal, and phytocannabinoids. |*Immunomodulation[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Cannabinoids/*therapeutic use[MESH] |Coronavirus Infections/*drug therapy[MESH] |Cytokines/immunology[MESH] |DNA/*therapeutic use[MESH] |Humans[MESH] |Interferon-alpha/*therapeutic use[MESH] |Pandemics[MESH] |Phytochemicals/therapeutic use[MESH] |Pneumonia, Viral/*drug therapy[MESH] |SARS-CoV-2[MESH]Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Sym(epmc).pdf DeepDyve Pubget Overpricing